{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:38:48Z","timestamp":1764916728036,"version":"3.46.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Relapse remains a major challenge in pediatric acute myeloid leukemia (AML), particularly in patients ineligible for hematopoietic stem cell transplantation (HSCT). Hypomethylating agents like azacitidine are hypothesized to target residual disease, but their efficacy and safety as maintenance therapy in\n                      <jats:italic>de novo<\/jats:italic>\n                      pediatric AML require validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective cohort study, 78 pediatric patients with\n                      <jats:italic>de novo<\/jats:italic>\n                      AML in remission after the C-HUANAN-AML 15 protocol were assigned to either azacitidine maintenance (n=27; subcutaneous 75 mg\/m\u00b2\/day, days 1-14 per cycle for 6 cycles) or observation (n=51) groups. Measurable residual disease (MRD) was monitored longitudinally via multiparameter flow cytometry (&amp;lt;0.1% threshold) and PCR for fusion transcripts. Key outcomes included event-free survival (EFS), overall survival (OS), cumulative incidence of relapse (CIR), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At a median follow-up of 34.6 months, azacitidine maintenance showed comparable EFS (77.7% vs. 77.0%, p = 0.688), OS (89.7% vs. 85.0%, p=0.368) and CIR (22.3% vs. 21.0%, p=0.838) to observation in the overall cohort. Subgroup analysis suggested a non-significant trend toward improved EFS (85.1% vs. 69.3%, p=0.198) and OS (92.9% vs. 81.6%, p=0.304) in intermediate-risk patients. However, among the 17 patients with core-binding factor AML (CBF-AML) and baseline fusion transcripts \u22650.1%, azacitidine maintenance (n=9) showed significantly superior EFS and CIR compared to observation (n=8) (EFS: 100% vs. 62.5%, p=0.048; CIR: 0.0% vs. 40.0%, p = 0.042). Although 40.7% of patients experienced grade 2-4 myelosuppression, all completed the treatment without dose reductions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Azacitidine maintenance therapy may sustain molecular remission in specific subgroups of pediatric AML, particularly CBF-AML patients with persistent MRD after induction who are ineligible for HSCT. However, the potential benefits must be weighed against the toxicity profile. The optimal dosing and scheduling require further investigation, and broader application warrants validation through larger, prospective, randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1696125","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:28:54Z","timestamp":1764916134000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Azacitidine as maintenance therapy in pediatric de novo acute myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Chunping","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nainong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111614","article-title":"A review of childhood acute myeloid leukemia: diagnosis and novel treatment","volume":"16","author":"Tseng","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030504","article-title":"Pediatric acute myeloid leukemia-Past, present, and future","volume":"11","author":"Reinhardt","year":"2022","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281106","article-title":"Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01619-9","article-title":"Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies","volume":"36","author":"Zarnegar-Lumley","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.12900","article-title":"A critical review of which children with acute myeloid leukaemia need stem cell procedures","volume":"166","author":"Hasle","year":"2014","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281810","article-title":"Maintenance therapy in acute myeloid leukemia: advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02836","article-title":"Homoharringtonine-based induction regimen improved the remission rate and survival rate in Chinese childhood AML: A report from the CCLG-AML 2015 protocol study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27583","article-title":"Maintenance therapy in AML: what is the future potential","author":"Goulart","year":"2025","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26847","article-title":"Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial","volume":"98","author":"Wei","year":"2023","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19924","article-title":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","volume":"206","author":"Sweet","year":"2025","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.975819","article-title":"Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia","volume":"10","author":"Xu","year":"2022","journal-title":"Front Pediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1186\/s12885-024-12828-z","article-title":"Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"24","author":"Pan","year":"2024","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B21","first-page":"163","author":"Kantarjian","year":"2024"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164171","article-title":"Risk-stratified therapy for pediatric acute myeloid leukemia","volume":"15","author":"Tomizawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20240722-00500","article-title":"Expert consensus on the diagnosis and treatment of pediatric acute myeloid leukemia (2024)","volume":"62","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.6004\/jnccn.2025.0006","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Inaba","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/children7020011","article-title":"Advances in pediatric acute promyelocytic leukemia","volume":"7","author":"Conneely","year":"2020","journal-title":"Children (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2383-2","article-title":"Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial","volume":"94","author":"Schweitzer","year":"2015","journal-title":"Ann Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003453","article-title":"Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study","volume":"5","author":"Hu","year":"2021","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251330064","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: A report from the Children\u2019s Oncology Group protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Borthakur","year":"2021","journal-title":"Blood Cancer J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0158-1","article-title":"Response kinetics and factors predicting survival in core-binding factor leukemia","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia","volume":"92","author":"Ragon","year":"2017","journal-title":"Am J Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26496","article-title":"Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia","volume":"97","author":"Senapati","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1696125\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:28:56Z","timestamp":1764916136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1696125\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1696125"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1696125","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1696125"}}